References
- RittbergerGeorge.Drugs and antidotes in acute intoxication. Critical Care Nephrology, Elsevier, 2019, s. 574-588.e3. https://doi.org/10.1016/B978-0-323-44942-7.00098-4
- Bujalski Michał, Wieczorek Łukasz, Sierosławski Janusz. Risk perception and risk aversion among people who use new psychoactive substances. Int J Drug Policy 2021: 97: 103326. https://doi.org/10.1016/j.drugpo.2021.103326
- Chung Eun Yong, Cha Hye, Min Hyun Kyu, i wsp. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. Arch Pharm Res 2021 Apr;44(4):402-413. https://doi.org/10.1007/s12272-021-01326-6
- Darke Shane, Duflou Johan, Farrell Michael, i wsp. Characteristics and circumstances of synthetic cannabinoid-related death. Clin Toxicol (Phila) 2020; 58(5): 368-374.https://doi.org/10.1080/15563650.2019.1647344
- Deen Adrian A, Claridge Hugh, Treble Richard D, i wsp. Deaths from novel psychoactive substances in England, Wales and Northern Ireland: evaluating the impact of the UK psychoactivesubstances act 2016. J Psychopharmacol 2021; 35(11): 1315-1323. https://doi.org/10.1177/02698811211026645
- Diaz James H. Syndromic diagnosis and management of confirmed mushroom poisonings. Crit Care Med 2005; 33(2): 427-36. https://doi.org/10.1097/01.CCM.0000153531.69448.49
- Dinis-Oliveira Ricardo Jorge, Magalhães Teresa. Abuse of licit and illicit psychoactive substances in the workplace: medical, toxicological, and forensic aspects. J Clin Med 2020; 9(3): 770. https://doi.org/10.3390/jcm9030770
- Dz. U. 2019 poz. 1745. Rozporządzenie Ministra Zdrowia z dnia 21 sierpnia 2019 r. zmieniające rozporządzenie w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych. Dostęp: http://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20190001745 (data wejścia: 20.10.2023).
- Emery Michael A, Eitan Shoshana. Members of the same pharmacological family are not alike: different opioids, different consequences, hope for the opioid crisis? Prog Neuropsychopharmacol Biol Psychiatry 2019: 92: 428-449. https://doi.org/10.1016/j.pnpbp.2019.02.010
- Fattore Liana, Marti Matteo, Mostallino Rafaela, i wsp. Sex and gender differences in the effects of novel psychoactive substances. Brain Sci 2020 Sep 3;10(9):606. https://doi.org/10.3390/brain-sci10090606.
- Gray Richard, Bressington Daniel, Hughes Elizabeth, i wsp. A systematic review of the effects of novel psychoactive substances ‘legal highs’ on people with severe mental illness. J Psychiatr Ment Health Nurs 2016; 23(5): 267-281. https://doi.org/10.1111/jpm.12297
- Higgins Kathryn, O’Neill Nina, O’Hara Leeanne, i wsp. New psychoactives within polydrug use trajectories-evidence from a mixed‐method longitudinal study. Addiction 2021; 116(9): 2454-2462. https://doi:10.1111/add.15422
- Kesner Andrew J, Lovinger David M. Cannabis use, abuse, and withdrawal: cannabinergic mechanisms, clinical and preclinical findings. J Neurochem 2021; 157(5):1674-1696. https://doi.org/10.1111/jnc.15369
- Madras Bertha K. The growing problem of New Psychoactive Substances (NPS). Neuropharmacology of New Psychoactive Substances (NPS). Curr Top Behav Neurosci 2017; 32:1-18. https://doi.org/10.1007/7854_2016_34
- Oficjalna strona internetowa Europejskiego Centrum Monitorowania Narkotyków i Narkomanii (EMCDDA). Dostęp: https://www.emcdda.europa.eu/data/stats2021/drd_en (data wejścia: 20.10.2023).
- Rinaldi Raffaella, Bersani Giuseppe, Marinelli Enrico, i wsp. The rise of new psychoactive substances and psychiatric implications: A wide‐ranging, multifaceted challenge that needs far‐reaching common legislative strategies. Hum Psychopharmacol 2020; 35(3): e2727. https://doi.org/10.1002/hup.2727
- Savulich George, Bowden-Jones Owen, Stephenson Robert, i wsp. Hot’ and ‘Cold’ cognition in users of club drugs/novel psychoactive substances. Front Psychiatry 2021; 12: 660575. https://doi.org/10.3389/fpsyt.2021.660575
- Shafi Abu, Berry Alex J, Sumnall Harry, i wsp. New psychoactive substances: a review and updates. Ther Adv in Psychopharmacol 2020; 10: 2045125320967197. https://doi.org/10.1177/2045125320967197
- Sharma Kirti Kumari, Hales Tim G, Jayathirtha Rao Vaidya, i wsp. The search for the “next” euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning. Forensic Toxicol 2019; 37(1):1-16. https://doi.org/10.1007/s11419-018-0454-5
- Specka Michael, Kuhlmann Thomas, Sawazki Jürgen, i wsp. Prevalence of Novel Psychoactive Substance (NPS) use in patients admitted to drug detoxification treatment. Front Psychiatry 2020, 11: 569. https://doi.org/10.3389/fpsyt.2020.00569
- Wieczorek Łukasz, Bujalski Michał, Dąbrowska Katarzyna. Negatywne konsekwencje wynikające z przyjmowania nowych substancji psychoaktywnych przez polskich użytkowników [Negative consequences of novel psychoactive substances use among the Polish users]. Psychiatr Pol 2021; 55(2): 447-469. https://doi.org/10.12740/PP/116140
- Wood David M, Dargan Paul I. The challenge of the novel psychoactive substances: How have we responded and what are theimplications of this response?. Br J Clin Pharmacol 2020; 86(3):407-409. https://doi.org/10.1111/bcp.14236
- Zawilska Jolanta B, Wojcieszak Jakub. An expanding world of new psychoactive substances-designer benzodiazepines. Neurotoxicology 2019; 73: 8-16. https://doi.org/10.1016/j.neuro.2019.02.015